[HTML][HTML] How to effectively treat acute leukemia patients bearing MLL-rearrangements?

D Steinhilber, R Marschalek - Biochemical pharmacology, 2018 - Elsevier
Chromosomal translocations-leading to the expression of fusion genes-are well-studied
genetic abberrations associated with the development of leukemias. Most of them represent …

BET bromodomain proteins regulate enhancer function during adipogenesis

JD Brown, ZB Feldman, SP Doherty… - Proceedings of the …, 2018 - National Acad Sciences
Developmental transitions are guided by master regulatory transcription factors. During
adipogenesis, a transcriptional cascade culminates in the expression of PPARγ and …

Disrupting acetyl-lysine interactions: recent advance in the development of BET inhibitors

F Zhang, S Ma - Current Drug Targets, 2018 - ingentaconnect.com
Background: Histone acetylation is an essential approach of post-translational modification
(PTM) and a significant component of epigenetic regulation that is mediated by …

Structure-based discovery of selective BRPF1 bromodomain inhibitors

J Zhu, C Zhou, A Caflisch - European journal of medicinal chemistry, 2018 - Elsevier
Bromodomain and plant homeodomain (PHD) finger containing protein 1 (BRPF1) is a
member of subfamily IV of the human bromodomains. Experimental evidence suggests that …

[HTML][HTML] BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability

LE Jennings, M Schiedel, DS Hewings, S Picaud… - Bioorganic & Medicinal …, 2018 - Elsevier
Ligands for the bromodomain and extra-terminal domain (BET) family of bromodomains
have shown promise as useful therapeutic agents for treating a range of cancers and …

Benzoxazinone-containing 3, 5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer

X Xue, Y Zhang, C Wang, M Zhang, Q Xiang… - European Journal of …, 2018 - Elsevier
The bromodomain and extra-terminal proteins (BET) have emerged as promising
therapeutic targets for the treatment of castration-resistant prostate cancer (CRPC). We …

Design, synthesis and biological evaluation of benzo [cd] indol-2 (1H)-ones derivatives as BRD4 inhibitors

Y Feng, S Xiao, Y Chen, H Jiang, N Liu, C Luo… - European journal of …, 2018 - Elsevier
Compound 1 bearing with benzo [cd] indol-2 (1H)-one scaffold was identified as an effective
BRD4 inhibitor through the AlphaScreen-based high-throughput screening and its high …

Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors

P Borysko, YS Moroz, OV Vasylchenko… - Bioorganic & Medicinal …, 2018 - Elsevier
A combination approach of a fragment screening and “SAR by catalog” was used for the
discovery of bromodomain-containing protein 4 (BRD4) inhibitors. Initial screening of 3695 …

Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups

J Hu, Y Wang, Y Li, D Cao, L Xu, SS Song… - European Journal of …, 2018 - Elsevier
Recently, several kinase inhibitors were found to also inhibit bromodomains, providing a
new strategy for the discovery of bromodomain inhibitors. Along this line, starting from PLK1 …

Y08060: a selective BET inhibitor for treatment of prostate cancer

Q Xiang, Y Zhang, J Li, X Xue, C Wang… - ACS medicinal …, 2018 - ACS Publications
Prostate cancer is a commonly diagnosed cancer and a leading cause of cancer-related
deaths. The bromodomain and extra terminal domain (BET) family proteins have emerged …